Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOX

Phase 2/3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Untreated, Unresectable, or Metastatic Colorectal Cancer

Conditions

Untreated, Unresectable, or Metastatic Colorectal Cancer

Trial Timeline

Dec 31, 2025 → Mar 11, 2034

NCT ID

NCT07221357

About Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOX

Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOX is a phase 2/3 stage product being developed by Bristol Myers Squibb for Untreated, Unresectable, or Metastatic Colorectal Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07221357. Target conditions include Untreated, Unresectable, or Metastatic Colorectal Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07221357	Phase 2/3	Recruiting	Dec 31, 2025	Mar 11, 2034	Untreated, Unresectable, or Metastatic Colorectal Cancer

Competing Products

15 competing products in Untreated, Unresectable, or Metastatic Colorectal Cancer

See all competitors

Product	Company	Stage	Hype Score
Veliparib + Placebo + Modified FOLFIRI + FOLFIRI + Bevacizumab + Fluorouracil infusion	AbbVie	Phase 2	52
Onureg + Venetoclax	AbbVie	Phase 1/2	41
Acalabrutinib + Rituximab + Chlorambucil	AstraZeneca	Phase 3	77
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin	AstraZeneca	Phase 2	52
Surovatamig + R-CHOP + R-CVP + BR	AstraZeneca	Phase 3	77
MK-3475 + Lenvatinib + Carboplatin + Paclitaxel	Merck	Phase 2	52
UFOX + Cetuximab + FOLFOX4 + Cetuximab	Merck	Phase 2	52
Rituximab + Prednisone + Doxorubicine + Cyclophosphamide + Vincristine	Roche	Phase 2	52
Rituximab + ACVBP regimen plus Pegfilgrastim	Amgen	Phase 2	51
Idelalisib + Nab-paclitaxel + mFOLFOX6	Gilead Sciences	Phase 1	32
PF-08634404 + Chemotherapy + Nivolumab	Pfizer	Phase 2/3	64
Nivolumab + Relatlimab	Bristol Myers Squibb	Approved	84
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	76
Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + Gemcitabine	Bristol Myers Squibb	Phase 2	51
Pumitamig + Folfox + Capox + Nivolumab	Bristol Myers Squibb	Phase 2/3	64

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved